NYSE:CHE - Chemed Stock Price, Forecast & News

Chemed trades on the New York Stock Exchange (NYSE) under the ticker symbol "CHE."

Chemed announced a quarterly dividend on Friday, November 1st. Shareholders of record on Monday, November 11th will be given a dividend of $0.32 per share on Monday, December 2nd. This represents a $1.28 dividend on an annualized basis and a yield of 0.27%. The ex-dividend date of this dividend is Thursday, November 7th. View Chemed's Dividend History.

Chemed declared that its Board of Directors has approved a stock buyback plan on Wednesday, March 7th 2018, which permits the company to repurchase $150,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization permits the company to repurchase shares of its stock through open market purchases. Stock repurchase plans are usually an indication that the company's board of directors believes its shares are undervalued.

Chemed Co. (NYSE:CHE) released its quarterly earnings data on Tuesday, October, 29th. The company reported $3.46 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $3.31 by $0.15. The business had revenue of $480.61 million for the quarter, compared to the consensus estimate of $478.89 million. Chemed had a return on equity of 35.06% and a net margin of 11.14%. The company's quarterly revenue was up 8.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $3.07 earnings per share. View Chemed's Earnings History.

Chemed is scheduled to release their next quarterly earnings announcement on Tuesday, February 18th 2020. View Earnings Estimates for Chemed.

Chemed will be holding an earnings conference call on Tuesday, February 18th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

4 brokerages have issued 1 year target prices for Chemed's shares. Their forecasts range from $405.00 to $500.00. On average, they anticipate Chemed's share price to reach $466.25 in the next year. This suggests that the stock has a possible downside of 2.3%. View Analyst Price Targets for Chemed.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chemed in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Chemed.

News stories about CHE stock have been trending somewhat positive on Tuesday, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Chemed earned a media sentiment score of 2.0 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Chemed.

Chemed saw a drop in short interest during the month of December. As of December 13th, there was short interest totalling 211,300 shares, a drop of 18.0% from the November 28th total of 257,700 shares. Based on an average daily volume of 89,500 shares, the short-interest ratio is presently 2.4 days. Currently, 1.4% of the company's shares are short sold. View Chemed's Current Options Chain.

Some companies that are related to Chemed include Laboratory Corp. of America (LH), Quest Diagnostics (DGX), Davita (DVA), Amedisys (AMED), LHC Group (LHCG), AMN Healthcare Services (AMN), BioScrip (BIOS), MEDNAX (MD), CorVel (CRVL), R1 RCM (RCM), Tivity Health (TVTY), The Providence Service (PRSC), Cross Country Healthcare (CCRN) and Interpace Diagnostics Group (IDXG).

Based on aggregate information from My MarketBeat watchlists, some companies that other Chemed investors own include Home Depot (HD), Altria Group (MO), AT&T (T), AbbVie (ABBV), CVS Health (CVS), Chevron (CVX), Walt Disney (DIS), Enterprise Products Partners (EPD), Occidental Petroleum (OXY) and Boeing (BA).

Chemed's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Riverbridge Partners LLC (2.29%), Boston Trust Walden Corp (0.75%), TSP Capital Management Group LLC (0.13%), Nisa Investment Advisors LLC (0.07%), Decatur Capital Management Inc. (0.06%) and Hanson & Doremus Investment Management (0.03%). Company insiders that own Chemed stock include David Patrick Williams, Donald E Saunders, Frank E Wood, George J Walsh III, Kevin J Mcnamara, Michael D Witzeman, Naomi C Dallob, Nicholas Michael Westfall, Patrick P Grace, Spencer S Lee, Thomas P Rice and Walter L Krebs. View Institutional Ownership Trends for Chemed.

CHE stock was sold by a variety of institutional investors in the last quarter, including Riverbridge Partners LLC, Nisa Investment Advisors LLC, NEXT Financial Group Inc, State of Alaska Department of Revenue, Decatur Capital Management Inc., Hanson & Doremus Investment Management, TrimTabs Asset Management LLC and TSP Capital Management Group LLC. Company insiders that have sold Chemed company stock in the last year include David Patrick Williams, Donald E Saunders, Frank E Wood, George J Walsh III, Kevin J Mcnamara, Michael D Witzeman, Naomi C Dallob, Spencer S Lee, Thomas P Rice and Walter L Krebs. View Insider Buying and Selling for Chemed.

CHE stock was acquired by a variety of institutional investors in the last quarter, including Boston Trust Walden Corp, Janney Montgomery Scott LLC, AE Wealth Management LLC, Calamos Advisors LLC, Private Trust Co. NA, First Hawaiian Bank, Louisiana State Employees Retirement System and Delta Capital Management LLC. Company insiders that have bought Chemed stock in the last two years include Donald E Saunders and George J Walsh III. View Insider Buying and Selling for Chemed.

Shares of CHE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CHE stock can currently be purchased for approximately $477.02.

Chemed has a market capitalization of $7.64 billion and generates $1.78 billion in revenue each year. The company earns $205.54 million in net income (profit) each year or $11.93 on an earnings per share basis. Chemed employs 15,707 workers across the globe.View Additional Information About Chemed.

The official website for Chemed is http://www.chemed.com/.

Chemed's mailing address is 255 EAST FIFTH STREET SUITE 2600, CINCINNATI OH, 45202. The company can be reached via phone at 513-762-6690.